Maze Therapeutics (NASDAQ:MAZE) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of Maze Therapeutics (NASDAQ:MAZE) to a strong-buy rating in a research note released on Thursday,Zacks.com reports.

A number of other equities research analysts also recently weighed in on MAZE. BTIG Research boosted their target price on Maze Therapeutics from $30.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Wells Fargo & Company assumed coverage on shares of Maze Therapeutics in a research note on Thursday, December 4th. They issued an “overweight” rating and a $55.00 target price on the stock. Wedbush boosted their price target on shares of Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Finally, Guggenheim raised their price objective on shares of Maze Therapeutics from $19.00 to $34.00 and gave the company a “buy” rating in a research note on Monday, September 15th. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Maze Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $43.38.

Maze Therapeutics Price Performance

Shares of MAZE opened at $41.71 on Thursday. The stock has a market cap of $2.01 billion and a PE ratio of -2.00. Maze Therapeutics has a 12 month low of $6.71 and a 12 month high of $43.29. The stock’s 50-day moving average is $34.55 and its two-hundred day moving average is $22.99.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Hedge Funds Weigh In On Maze Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MAZE. Frazier Life Sciences Management L.P. acquired a new position in shares of Maze Therapeutics in the first quarter valued at approximately $45,460,000. ARCH Venture Management LLC acquired a new position in Maze Therapeutics in the 1st quarter valued at $45,362,000. Matrix Capital Management Company LP bought a new position in Maze Therapeutics during the 1st quarter worth $27,373,000. Woodline Partners LP acquired a new stake in shares of Maze Therapeutics during the first quarter worth $10,229,000. Finally, Vanguard Group Inc. boosted its position in shares of Maze Therapeutics by 218.1% in the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after acquiring an additional 915,342 shares during the period.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.